Drug Profile


Alternative Names: Centella-asiatica/Echinacea-purpurea/Sambucus-nigra; IZN 6N VS; IZN-6N-AV

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Izun Pharma
  • Class Anti-inflammatories; Herbal medicines
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Vaginitis

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Vaginitis in Israel (Topical, Cream)
  • 01 Dec 2014 Izun Pharmaceuticals initiates a phase I/II trial in Vaginitis in Israel (NCT02313545)
  • 13 May 2013 Izun Pharmaceuticals plans a proof-of-concept trial for Vaginitis in Israel
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top